插管前经鼻高流量氧疗时间延长与重症ARDS患者生存及成功脱离V-V ECMO的关联:一项回顾性多中心研究
该回顾性多中心研究基于J-CARVE登记数据,分析2012-2022年209例接受V-V ECMO前使用HFNC的重症ARDS成人。多因素logistic回归显示插管前HFNC时间(连续变量)为60天院内死亡的独立危险因素(aOR 1.22/天,95%CI 1.07-1.39,P=0.0035)。以探索性ROC界值分为短HFNC组(<3天)与长HFNC组(≥3天,69例,33.0%),校正后长HFNC组60天院内死亡风险约翻倍(aHR 2.27,95%CI 1.24-4.15,P=0.008),成功脱离ECMO显著更低(aSHR 0.68,95%CI 0.50-0.94,P=0.018)。作者认为延长HFNC更可能是反映疾病轨迹与延迟升级的复杂预后标志,而非直接损伤原因,临床应将延长HFNC视为累积风险的连续轨迹,而非仅凭IMV时长决定ECMO启动。
要点
- 插管前HFNC时间作为连续变量,每延长1天,60天院内死亡风险独立增加(aOR 1.22,95%CI 1.07-1.39,P=0.0035)。
- 以≥3天为界,长HFNC组60天院内死亡风险约翻倍(aHR 2.27,95%CI 1.24-4.15,P=0.008),69例(33.0%)属该组。
- 长HFNC组成功脱离V-V ECMO显著更低(aSHR 0.68,95%CI 0.50-0.94,P=0.018)。
- 作者认为延长HFNC更可能是反映疾病轨迹与延迟升级的复杂预后标志,而非直接损伤原因。
- 临床应将延长HFNC视为累积风险的连续轨迹,而非仅凭IMV时长指导ECMO启动。
适用人群与场景
- 2012-2022年J-CARVE登记中接受V-V ECMO前使用HFNC的重症ARDS成人患者209例。
诊断标准与关键阈值
- 以探索性ROC推导的界值将患者分为短HFNC组(<3天)与长HFNC组(≥3天)。
研究设计与关键结果
- 研究类型:基于J-CARVE登记的回顾性多中心研究,纳入209例接受V-V ECMO前使用HFNC的重症ARDS成人(2012-2022年)。
- 主要终点:多因素logistic回归显示插管前HFNC时间(连续变量)为60天院内死亡的独立危险因素(aOR 1.22/天,95%CI 1.07-1.39,P=0.0035)。
- 分组:长HFNC组(≥3天)69例(33.0%),短HFNC组(<3天)为对照。
- 校正后长HFNC组60天院内死亡风险约翻倍(aHR 2.27,95%CI 1.24-4.15,P=0.008)。
- 长HFNC组成功脱离ECMO显著更低(aSHR 0.68,95%CI 0.50-0.94,P=0.018)。
证据类型、等级与局限
- 证据类型:回顾性多中心研究(基于J-CARVE登记)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为延长HFNC更可能是反映疾病轨迹与延迟升级的复杂预后标志,而非直接损伤原因。
- 作者建议临床应将延长HFNC视为累积风险的连续轨迹,而非仅凭IMV时长指导ECMO启动。
指南或共识出处
- J-CARVE登记(2012-2022年)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with severe acute respiratory distress syndrome (ARDS), prolonged invasive mechanical ventilation (IMV) prior to veno-venous extracorporeal membrane oxygenation (V-V ECMO) is a known risk factor for poor outcomes. However, the clinical impact of high-flow nasal cannula (HFNC) duration before intubation remains poorly defined. We examined the association between pre-intubation HFNC duration and clinical outcomes, including survival and ECMO liberation.
METHODS: This retrospective multicenter study using the J-CARVE registry analyzed 209 adults with severe ARDS who received HFNC before V-V ECMO (2012-2022). The continuous risk of prolonged HFNC for 60-day in-hospital mortality was evaluated using multivariable logistic regression. Subsequently, patients were stratified into Short (< 3 days) and Long (≥ 3 days) HFNC groups using an exploratory ROC-derived cutoff. Clinical outcomes (60-day in-hospital mortality and successful ECMO liberation) were further analyzed using multivariable Cox and Fine-Gray models.
RESULTS: Multivariable logistic regression identified prolonged HFNC duration (analyzed continuously) as an independent risk factor for 60-day in-hospital mortality (adjusted odds ratio 1.22 per 1-day increase; 95% CI 1.07-1.39; P = 0.0035). Sixty-nine patients (33.0%) were in the Long HFNC group. After adjustment, prolonged HFNC (≥ 3 days) was independently associated with a twofold increase in 60-day in-hospital mortality (adjusted Hazard Ratio 2.27; 95% CI 1.24-4.15; P = 0.008). Furthermore, successful ECMO liberation was significantly lower in the Long HFNC group (adjusted Subdistribution Hazard Ratio 0.68; 95% CI 0.50-0.94; P = 0.018).
CONCLUSIONS: Extended pre-intubation HFNC duration was associated with increased mortality and impaired lung recovery in severe ARDS. Rather than a direct cause of injury, prolonged HFNC likely serves as a complex prognostic marker reflecting disease trajectory and delayed escalation. Clinicians should recognize prolonged HFNC as a continuous trajectory of accumulating risk, rather than relying solely on IMV duration to guide ECMO initiation.
参考来源
- Nakayama R, Bunya N, Nishikimi M, et al. Association of prolonged pre-intubation high-flow nasal cannula duration with survival and successful V-V ECMO liberation in severe ARDS: a retrospective multicenter study. J Intensive Care. 2026. PMID: 42638121. doi:10.1186/s40560-026-00915-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。